We studied the methylome in three collections of human postmortem brain (N=206) and blood samples (N=1,132) of subjects with major depressive disorder (MDD) and controls. Using an epigenomic deconvolution approach we performed celltypespecific methylomewide association studies (MWAS) within subpopulations of neurons/glia and granulocytes/Tcells/Bcells/monocytes for bulk brain and blood data, respectively. Multiple MWAS findings in neurons/glia replicated across brain collections (ORs=509538, Pvalues<1x10 5 ) and were reproducible in an arraybased MWAS of sorted neurons/glia from a fourth brain collection (N=58). Pathway analyses implicated p75 NTR /VEGF signaling, neurodegeneration, and bloodbrain barrier perturbation. Celltype specific analysis in blood identified associations in CD14+ monocytes a cell type strongly linked to neuroimmune processes and stress. Top results in neurons/glia/bulk and monocytes were enriched for genes supported by GWAS for MDD (ORs=2.022.87, Pvalues=0.003 to <1x10 5 ), neurodegeneration and other psychiatric disorders. In summary, we identified novel MDDmethylation associations by using epigenomic deconvolution that provided important mechanistic insights for the disease.
Major depressive disorder (MDD) is a mental illness characterized by marked and persistent dysphoria 1 . Because the disease has high lifetime prevalence (~15%) 2 , can start early in life, and typically involves a chronic course, the World Health Organization ranks MDD as the leading cause of disability 3 . DNA methylation studies offer unique opportunities to better understand and treat MDD by improving our understanding of the involvement of DNA methylation in the dynamic features (e.g., episodic nature, course) of MDD and by providing insight into how environmental risks (e.g., stress) can impact symptom severity 46 . Importantly, methylation studies have profound translational potential, as methylation is modifiable by treatment and can potentially be used as biomarkers to improve diagnosis and clinical disease management.
Methylomewide association studies (MWAS) are ideally performed in the tissues where the pathogenic processes likely manifest. There exists good evidence that MDD has a systemic component that involves both brain and peripheral immune cells 7, 8 . Therefore, we sought to characterize MDDlinked methylation changes in both brain and blood.
MWAS is typically performed using DNA from bulk tissues containing multiple cell types. Failure to account for these multiple cell types has several drawbacks 9 . Most recognized is the risk of false positive associations that occurs when the abundance of cell types varies across samples included in the study 10, 11 . Underappreciated is the negative impact of cell type heterogeneity on the statistical power to detect associations with disease. Thus, casecontrol differences may be of opposite directions between cell types, resulting in "diluted" and/or "canceled out" effect sizes in bulk tissue. Furthermore, as the most common cell types will drive the results, associations present in low abundance cells may remain undetected in bulk tissue. Finally, knowing what cell type harbors an association is key for the biological interpretation of findings and can be critical for designing proper functional followup experiments.
It is not practically or fiscally feasible to perform methylation assays on isolated cell populations at the sample sizes required for adequately powered MWAS. A practical solution is to apply statistical methods that are informed by data from reference sets of sorted cells to deconvolute the celltypespecific effects from data For each subject at a time, bulk methylation data is regressed on the most informative sites in the reference methylomes to obtain estimated proportions of each cell type. (B) Once cell type proportions have been estimated for each subject in the study, step 2 uses these proportions to estimate casecontrol differences at site each CpG site at a time. (C) To illustrate how celltypespecific differences are estimated we present a simple example. Since bulk methylation and proportions of neurons/glia will differ between subjects, we can regress bulk methylation levels (Yaxis) on the proportion of neuronal cells (Xaxis). Thus, extrapolating the regression line to the point where the proportion of neurons is zero (i.e., there are only glia cells) estimates the group mean methylation in glia, and extrapolation to the point where the proportion of neurons is one estimates the group mean methylation in neurons. By allowing the regression lines to differ between controls (black dots) and cases (red crosses), we obtain different predicted celltypespecific group means that can be tested for significance using standard statistical tests. See Online Methods and Supplemental Note 1 for discussion of the statistical models.
from reference sets of sorted cells to deconvolute the cell typespecific effects from data generated with bulk tissue 12 . This deconvolution approach is commonly used in expression studies but can readily be applied to methylation data 13, 14 . The method has been validated using predesigned mixtures of cell types and applications using empirical data have confirmed its value by revealing associations undetectable in bulk tissue 15 .
In the largest and most comprehensive study to date, we examined methylation differences between MDD cases and controls in bulk brain samples from three collections totaling 206 individuals, as well as in 1,132 independent blood samples. Applying an epigenomic deconvolution strategy to bulk tissue data, we performed methylomewide association studies (MWAS) within cell populations mainly consisting of neurons/glia and granulocytes/Tcells/Bcells/monocytes. Associations detected in one set of brain collections were replicated in the others using a stringent "roundrobin" design. We further validated top celltypespecific associations obtained via epigenomic deconvolution against those observed in sorted neuronal and glial nuclei from brains of an additional 58 casecontrol subjects. Finally, we tested for overrepresentation of genes implicated by our top MWAS findings among those identified in recent GWAS for MDD and related disorders.
RESULTS
Complete descriptions of study participants, data quality control, and analyses are provided in the Supplementary Methods.
Celltypespecific MWAS in brain
We used sequencingbased methylation data from a total of 206 postmortem brain samples from three collections 16 (Table S1) .
To obtain sequencingbased reference methylomes for neurons and glia, we used fluorescence activated cell sorting (FACS) to isolate neuronal and glial nuclei from cortex of five individuals (Online Methods). These reference methylomes enabled us to test for cell typespecific casecontrol differences in samples for which only bulk tissue data was available. The principles underlying this epigenetic deconvolution approach 13, 15 are illustrated in Figure 1 . Implementation details for the method are presented in Online Methods and Supplemental Note 1.
Estimated proportions of neurons and glia (~1:3) matched proportions expected in cortex based on the literature 17 and showed no significant casecontrol differences. QuantileQuantile (QQ) plots for the celltype specific MWASs (Figure S3 ) displayed deviations from the 95% confidence interval for small Pvalues suggesting multiple CpGs had discernible effects within cell types. Further, MWASs of permuted casecontrol status for each analysis yielded average lambdas that were not significantly different from 1 ( Figure S4) , which indicated that our observed Pvalues were accurate and did not show evidence of inflation. Additional validation analyses for the deconvolution method are detailed in the Online Methods.
To replicate findings in brain we used a stringent roundrobin design (Figure 2) . In each round, a meta analysis of two of three datasets ("minimeta") was used for discovery (P<0.01), and the remaining dataset was used for replication (P<0.05), where direction of effect for discovery/replication must be equal. Markers that met these criteria in at least two of the three roundrobin iterations were considered to have replicated. Permutation tests ( Roundrobin replication design for neuron/glia/bulk MWAS in three brain collections. We performed a discovery MWAS by performing a metaanalysis using only two of the three individual MWASs. Results from this discovery "minimeta" were then replicated in the remaining independent. Within each of the three possible rounds, a Pvalue threshold of 0.01 was used for discovery minimeta results. Top discovery sites were considered to replicate if P<0.05 in the replication set and filtered for equal direction of effect. Finally, only replicating sites that were implicated in at least two of the three possible round robin iterations were considered to have survived the protocol. 3 Neurons & Glia A total of 4,330/3,882 replicating CpGs that implicated 1,784/1,682 genes were observed for neurons and glia, respectively (Tables S2 & S3) . Interestingly, 1,683 CpGs were detected in both neurons and glia and were found in genes such as HERC2, RNF111, and TRIM3 that all encode ubiquitin ligases that have roles in neurodevelopment and synaptic plasticity 1823 . HERC2 has also been previously associated with autism 24 . Top findings that were unique to neurons included genes like RAPGEF6 and FAM63B. Interestingly, RAPGEF6 has also been strongly associated with schizophrenia and has been shown to impact anxietylike behavior in mice 25, 26 . Encoding the deubiquitinase MINDY2, FAM63B was a top finding from two past methylation studies of schizophrenia 27 and bipolar disorder 28 . Finally, among top unique glia findings was a site within the gene HMCN1, which has been previously associated with postpartum depression 29 .
Considering the known effects of DNA methylation on distal regulatory elements, we tested whether our MWAS findings overlapped with Roadmap Epigenomics Project chromatin state tracks 30 . In general, results for neurons and glia were not overrepresented at chromatin states associated with regulatory features (Table S4) . However, as the Roadmap Epigenomics Project chromatin state tracks for brain were generated in bulk tissue, they likely are not representative for many celltypespecific chromatin states.
We tested results for enrichment of KEGG/ Reactome pathways using a permutationbased method that properly controls for the number of CpGs in a gene and the presence of correlated sites. Furthermore, this approach allows for a correction for testing multiple pathways with overlapping genes (Online Methods). To identify groups of pathways driven by the same MWAS findings, we further clustered the pathways that remained significant after correcting for multiple testing (familywise error rate<0.05) based on the presence of overlapping genes.
Results for neurons were significantly overrepresented in genes belonging to 14 pathways (Table S5 ) and formed five clusters ( Figure 3A) . The first cluster (red) was related to p75 NTR receptormediated signaling (OR=3.84, P=0.0017) and related neuronal cell death processes. A second cluster (yellow) was related to 
Complementary Analyses in Sorted Neurons & Glia
To check the celltypespecific results obtained via epigenomic deconvolution, we also performed MWAS on arraybased methylation data from FACS isolated neuronal (28 MDD, 29 control) and glial (29 MDD, 29 control) nuclei of postmortem frontal cortex samples 31 ( Figures S7 & S8) . We next tested for enrichment between the replicating sites from our sequencingbased celltypespecific MWASs (above) and the top results from the arraybased sorted datasets (Tables S7 & S8) , using two Pvalue thresholds of 0.05 and 0.01 for replication in the latter. It should be noted that only a small fraction of CpGs assayed in our sequencingbased data are also assayed by arraybased approaches. For example, of the 4,330 replicating CpGs for deconvoluted neurons, only 169 could be mapped to CpGs actually measured in the arraybased dataset.
Nonetheless, despite the limited sample size and scope of the sorted data, results for deconvoluted neurons were significantly enriched among top Tables S9 & S10 ) that were also implicated in deconvoluted neurons and glia. Notably, sorted neurons ( Figure 3B) were enriched for Caspase mediated cleavage of cytoskeletal proteins (OR=7.67, P=0.0165) which is a central apoptotic process and involved in neuronal cell death 32, 33 . Pathways involving adherens junctions and focal adhesion molecules were similarly shared between results for sorted and deconvoluted neurons. Remarkably, the major pathway cluster (green, Figure S4B ) for sorted glia contained terms related to, for example, Cadependent events (OR=4.76, P=0.0074), which closely mirrored results for deconvoluted glia. Together, these results strongly support the veracity and robustness of the celltype specific effects detected by the epigenomic deconvolution approach.
Bulk Brain
Analysis of bulk brain may provide better power to detect casecontrol differences that influence multiple cell types in a similar fashion. Therefore, we also applied the round robin protocol to MWAS of the bulk brain methylation data, identifying 4,048 MDDassociated CpGs that replicated and implicated 1,786 genes ( Table S11 ). The top findings in bulk brain included sites located in RBFOX1, TMEM44, and PREX1. Variants in the RNA slicing regulator RBFOX1 obtained genomewide significance in a recent metaanalysis of large MDD GWASs 34 . In plasma, TMEM44 has been associated with circulating levels of the proapoptotic tumor necrosis factor receptor 1 (TNFR1) 35 . In rodent models, deficits in Table S5 for deconvoluted neurons and Table S9 for sorted neurons. Table S6 for deconvoluted glia and Table S10 for sorted glia.
Prex1 results in autismlike behavior 36 and is associated with antidepressant response in humans 37 . Interestingly, very few associations that were detected in deconvoluted neurons (1 CpG) or glia (14 CpGs) were also detected in bulk, suggesting celltypespecific effects are indeed diluted or obscured in bulk tissue.
Results for bulk brain were overrepresented in regulatory regions such as Bivalent/Poised TSS (OR=2.77, P=0.0003) and Flanking Bivalent TSS/ Enhancer (OR=2.70, P=0.0238) ( Table S4) . A total of 10 pathways (Table S12) were significantly overrepresented among the results for bulk brain spread across five clusters ( Figure 5) 
Celltypespecific MWAS in blood
For blood, we used sequencingbased data from 1,132 whole blood samples 16 (812 MDD and 320 controls) from the Netherlands Study of Depression and Anxiety (NESDA) 38 . For deconvolution of blood cell types, we used sequencingbased references 39 from leukocyte populations isolated from six human whole blood samples using antibodies against CD15, CD3, CD19, and CD14 that are expressed on the surface of granulocytes, Tcells, Bcells, and monocytes, respectively 40 .
Mean estimated cell type proportions were 55.8, 31.3, 9.3, and 3.6% for CD15, CD3, CD19, and CD14 Table S12 for bulk brain.
respectively. With the exception of CD14, the estimated cell type proportions differed significantly between cases and controls. Notably, MDD cases tended to have increased myeloid cell and decreased lymphocyte levels as expected 41, 42 .
CD15, CD3, CD14, & CD19
As a complementary dataset was unavailable for replication of the NESDA sample, we applied an appropriate false discovery rate (FDR) of 0.1 for declaration of methylomewide significance 43, 44 in cell typespecific MWAS in blood. The QQplots (Figure S5 ) suggested the main association signals involved CD3 (T cells) and CD14 (monocytes), which yielded multiple methylomewide significant results. No significant findings from celltypespecific MWAS in CD15 or CD19 were observed. Permutations of casecontrol status for each MWAS in CD3 and CD14 displayed mean lambda values that were not significantly different from 1 ( Figure S6) , again suggesting the observed effects were not due to uncontrolled artifacts.
In CD3, 18 CpGs passed methylomewide significance (Table S14) . Genic findings for CD3 involved STRADB, FLI1/SENCR, and KIAA1217. Due to the scarcity of methylomewide significant results for CD3, functional annotation and pathway analyses are not presented.
The MWAS for CD14 identified 372 methylome wide significant CpGs representing 129 genes (Table  S15) . Among the top genic findings for CD14 were ITPR2, SVOPL, TP53, ARNT2, SHANK2, KATNAL2, and GRIA1. Findings for CD14 were significantly enriched (OR=52.8, P=0.0063) at active transcriptional start sites for monocytes (Table S4) . Top CD14 MWAS results showed overrepresentation of genes involved in 15 pathways (Table S16) that resulted in five clusters (Figure 6 ). The largest pathway cluster in CD14 (red) contained pathways involving Glutamatergic synapse (OR=15.0, P=0.0007) and Oxytocin signaling pathway (8.85, P=0.0061).
Whole Blood
Top findings in whole blood 16 (e.g., top site P=1.91x10 8 ) did not pass the FDR threshold of 0.1 employed in the current analysis. This again suggests that many effects in individual cell types may counter each other and leave many associations obscured in whole blood. Alternatively, as the blood cell types showing the largest signals are of relatively low abundance (CD3 and CD14), statistical power may be lacking to detect many of these differences as they represent a minority of cells.
Celltypespecific MWAS of antidepressant treatment
Given the potential for antidepressant drug treatment to affect the methylome 45 we also sought to determine the celltypespecific effects of drug treatment. Biographical information for postmortem brain samples often lack treatment history and precluded such an analysis in the brain datasets. However such information was available in NESDA, where we performed celltypespecific MWAS with MDD cases that were treated (N=450) or untreated (N=362) with antidepressants. Antidepressant treatment was associated (FDR=0.1) with 3 CpGs in CD3 and 359 CpGs in CD14. Importantly, no sites that were associated with antidepressant treatment were also among top MDD findings in CD3 and CD14 MWASs. Thus, celltype specific associations to MDD in CD3 and CD14 were not simply due to drug treatment, and vice versa. Table S16 for CD14.
Top findings are overrepresented at genes from GWAS of MDD and other neuropsychiatric disorders
We looked for convergence of evidence between our cell typespecific MWASs and the top 10,000 variants from six recent GWAS metaanalyses for attentiondeficit/ hyperactivity disorder (ADHD) 46 , anxiety disorders 47 , autism spectrum disorder (ASD) 48 , bipolar disorder (BPD) 49 , MDD 34 , and schizophrenia 49 . Additionally, given that our results consistently implicated pathways involved in neuronal apoptosis, we looked for overlap between MWAS results and 869 top GWAS sites for neurodegenerative disorders from NHGRIEBI GWAS Catalog data 50 .
Genetic variants and methylation markers likely exert effects on a given gene at distally remote loci (e.g. promoters versus distal proteincoding sequence). Therefore, we tested for significant enrichment between the genes implicated by top MWAS and GWAS sites, while accounting for local correlations and number of sites per gene (Online Methods). To check for specificity, we also tested for overlap of our top MWAS findings versus the top 10,000 variants from a recent GWAS meta analysis of breast cancer 51 .
As expected, no MWAS results were enriched at genes associated with breast cancer. In contrast, results ( Table 2) showed very robust and highly significant enrichment between genes implicated by MDD GWAS and those replicating across neuron, glia, and bulk brain MWAS results. Albeit less robust, replicating CD14 MWAS results were also significantly enriched at genes from MDD GWAS. Testing also yielded significant overlap of genes between bulk brain MWAS and GWAS for BPD and neurodegenerative disorders. Results for neuron MWAS were further enriched for genes associated with ADHD, ASD, and BPD. Glial MWAS findings were also enriched for ADHD and BPD genes, as well as those for neurodegenerative disorders.
DISCUSSION
In the most comprehensive methylation study of MDD to date, we characterized methylomewide associations in large collections of brain and blood samples at a cell typespecific level. Using a roundrobin replication procedure, we identified novel associations with MDD in neurons and glia that replicated across three brain collections and in a fourth sample of sorted nuclei. Cell typespecific MWASs in blood uncovered associations in CD14+ monocytes that were not detected in whole blood. Strong overlap with past GWAS studies of MDD and neurodegenerative disorders also supported the robustness of our MWAS findings.
We obtained our results by employing an epigenomic deconvolution strategy to perform MWAS on individual subpopulations of neurons/glia and granulocytes/Tcells/Bcells/monocytes, respectively. The robustness of this strategy was demonstrated through a series of validation analyses (Online Methods). Cell typespecific associations for deconvoluted neurons/glia also replicated across brain sample collections. Critically, overlap in terms of genes and pathways was found with MWASs that involved sorted neurons/glia. Finally, top results from celltypespecific MWASs were significantly enriched for genes implicated by external GWAS of MDD and related disorders. Taken together, this converge of evidence supports the value of the deconvolution strategy 8 as a costeffective approach to detect celltypespecific associations.
The overall results across brain cell types heavily implicated neurotrophinlinked degenerative pathways in MDD. The nerve growth factor receptor (p75 NTR ) regulates neuronal apoptosis via interacting proteins such as NRAGE, JNK, and Rac. A fine balance of neurotrophin signaling through the generally prosurvival Trk receptors and apoptotic p75 NTR is needed for normal neurodevelopment and neuron survival 52 . Notably, our results suggested differences in p75 NTR signaling among both neurons and glia of MDD cases and controls. While less well studied, glia also express p75 NTR where it is important for oligodendrocyte development and astroglial response to injury and insult 53 .
Patients with treatmentresistant MDD have reduced cortical grey matter density 54 . These grey matter reductions appear to be due to a diminished neuronal cell size paired with decreased densities of glia in MDD patients 55, 56 . Further, in rat models of depression, glial ablation in the prefrontal cortex was sufficient to induce depressionlike behaviors 57 . Thus, these grey matter alterations in MDD may be partially mediated by p75 NTR linked apoptotic processes. While we did not observe significant differences in estimated neuron:glia ratios between MDD cases and controls in our samples, such ratios do not reflect absolute differences in cell numbers between groups.
Analysis of top bulk brain findings also demonstrated enrichment for vascular endothelial growth factor (VEGF) and nitric oxide (NO) signaling pathways. While more extensively studied as an angiogenic factor, some evidence has accumulated for VEGF as a neuroprotective factor with links to MDD 58 . In vascular endothelial cells, VEGF regulates NO synthase expression where it interacts with the p75 NTR in opposing fashion 59, 60 . A similar action for VEGF is seen in brain vasculature under pathological conditions where VEGF increases bloodbrain barrier (BBB) permeability 61 . Thus, our findings implicating VEGF and p75 NTR signaling may reflect alterations in BBB integrity in MDD.
It is also interesting to note that MWAS results for neurons were significantly enriched for circadian entrainment pathways. Sleep disruption presents in 50 95% of depression cases and is correlated with severity and susceptibility to recurrent depression 62, 63 . These circadian disruptions can be seen in abnormal temporal expression of canonical clock genes in brain regions outside the suprachiasmatic nucleus, such as prefrontal cortex 64 . Whereas our MWAS results did not involve canonical clock genes, many intermediate enzymes and second messenger systems (e.g. calciumdependent kinases, adenylyl cyclases) drove the enrichment of circadian entrainment pathways. Pathways linked to these calciumdependent second messenger systems were also prominently featured among results for glia. Like neurons, astrocytes express circadian rhythms 65 . Given the centrality of calcium signaling in astrocyte biology 66 , glial defects may also contribute to altered circadian rhythm in MDD.
Finally, the most significant MWAS findings among blood cell types were observed in CD14+ monocytes. Considerable evidence has shown that psychological stress activates potent immune responses via the hypothalamicpituitaryadrenal axis 67 which leads to epigenetic reprogramming of monocytes and microglia 42, 68, 69 . These primed immune cells inturn display a proinflammatory phenotype to future stress and 42, 70, 71 . Curiously, the most significant pathway implicated in monocytes was related to glutamatergic signaling, which was also implicated in neurons. We did not observe the same methylation sites in the top of the MWAS from neurons and CD14, thereby suggesting any systemic component to MDD involves interactions between blood and brain rather than coincident changes in identical methylation sites. How glutamatergic signaling could impact monocytic biology in the context of a bloodbrain interaction is not immediately clear. However, social stress has been shown to lead to depressionlike behavior via disruption of the BBB 72 . Excess glutamate also increases BBB permeability and facilitates transmigration of monocytes into the brain 73, 74 .
While glutamate does not appear to be a chemoattractant for peripheral monocytes 75 , other glutamatergic ligands like the kynurenine metabolites kynurenic acid and quinolinic acid, can activate monocytes 7577 . Further, severe depression has been associated with increased microglial production of quinolinic acid 78 , which inturn stimulates astrocytes to secrete monocyte chemoattractant protein1 (CCL2) 79 . Disruption of the BBB in depression may facilitate leakage of glutamate and/or kynurenine and its metabolites into circulation. Indeed, increased plasma concentrations of glutamate 80 and kynurenine 81 have been recently observed in MDD in other cohorts. Thus, methylation changes linked to glutamatergic signaling in neurons and monocytes may reflect responses to a broader excitotoxic or neuroinflammatory state. Such a model of stress induced BBB changes and/or excitotoxicity in MDD also appear supported by our MWASs in brain involving p75 NTR , VEGF, and cortisol pathways.
One limitation in studies involving biological samples from human patients is the potential confound of drug treatment. Since antidepressant treatment is highly correlated with MDD diagnosis, such a confound is largely unavoidable for postmortem samples. However, treatment information was available for the NESDA sample. Whereas many methylomewide significant effects were associated with antidepressant treatment in CD3 and CD14, our top casecontrol findings in blood cell types did not contain any antidepressantassociated sites. Therefore, drug treatment was not a significant confound in our analyses.
In conclusion, our celltypespecific MWASs revealed many associations otherwise obscured in bulk brain and whole blood, and provided unique mechanistic insights into the underlying disease processes. This highlights the utility of deconvolution methods as valuable approaches for performing MWAS in human samples for which only bulk tissue data is available. In addition to finding significant association signals for MDD in the neurons of the postmortem brain samples, we also found ample evidence for a role of glia in MDD. These findings are notable in light of the historically underappreciated role of glia in disease. Celltypespecific analyses in blood strongly suggested a role for monocytes in MDD pathology and appears to corroborate animal studies linking monocytes to stressinduced behaviors, and supports a systemic model of MDD pathology. Collectively, top MWAS findings and secondary analyses pointed towards neurodegeneration and increased BBB permeability, potentially via p75 NTR /VEGF signaling, as key components of such a systemic model. These pathways merit additional research and serious consideration as novel therapeutic targets for MDD. Lastly, top MWAS results were consistently enriched at genes previously associated with MDD, related neuropsychiatric disorders, and neurodegenerative disorders. Such overlap with external studies bolsters the veracity of our results and further highlights the shared liabilities among neuropsychiatric disorders.
METHODS
Methods and any associated references are available in the Online Methods
